Abstract: The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
January 3, 2023
Assignee:
Genome Protection, Inc.
Inventors:
Andrei V. Gudkov, Vadim Mett, Vadim Krivokrysenko
Abstract: The present invention relates to the fields of medical microbiology and vaccines. In particular the invention relates to a process wherein the spontaneous release of bacterial outer membrane vesicles (OMV) of Gram-negative bacteria is stimulated by application of a dissolved oxygen tension (DOT) that is higher than a physiological DOT. The thus produced OMVs are for use in vaccines. The invention further relates to OMV obtainable by said process, and to a pharmaceutical composition comprising such OMV. The present invention further relates to the use of OMV of the present invention as a medicament in particular for use in a method for eliciting an immune response.
Type:
Grant
Filed:
December 4, 2018
Date of Patent:
January 3, 2023
Assignee:
Intravacc B.V.
Inventors:
Matthias Joannes Hendrikus Gerritzen, Leonardus Aldolfus van der Pol, Michiel Stork
Abstract: A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder and in particular, provides honey bees with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.
Abstract: The present invention provides a novel Lactobacillus fermentum strain, named Lactobacillus fermentum strain V3, and its use in manufacturing a pharmaceutical composition or a food composition for regulating intestinal microflora and treating and/or preventing an inflammatory diseases and/or a cancer.
Abstract: Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.
Type:
Grant
Filed:
March 19, 2019
Date of Patent:
December 20, 2022
Assignees:
Northwestern University, Cornell University
Inventors:
Michael Christopher Jewett, Jessica Carol Stark, Matthew P. DeLisa, Thapakorn Jaroentomeechai
Abstract: The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
Type:
Grant
Filed:
December 21, 2020
Date of Patent:
November 22, 2022
Assignee:
Applied Molecular Transport Inc.
Inventors:
Thomas Carl Hunter, Randall J. Mrsny, Weijun Feng, Tahir Mahmood, Charles Olson, Sally Postlethwaite
Abstract: Described herein are methods of treating, diagnosing, and/or prognosing a disease in a subject relating to detection of the glycosylation state of the antibodies present in the subject. In some embodiments, the disease can be an infection. In some embodiments, an antibody glycosylation state that is indicative of the presence of a disease, or a need for treatment of a disease can be reduced glycosylation (e.g., galactosylation, sialation, fucosylation, and/or afucosylated branched glycoforms).
Type:
Grant
Filed:
August 20, 2020
Date of Patent:
November 15, 2022
Assignees:
THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: The present application provides methods and uses of O-oligosaccharyltransferase (O-OTases) for generating vaccines. In particular, the present application provides a method of synthesizing a glycoprotein comprising glycosylation of pilin-like protein ComP using a Pg1LComP O-OTase. Uses of glycoproteins synthesized by glycosylating ComP using Pg1LComP O-OTase, particularly for the preparation of vaccines and the like, including a vaccine to Streptococcus, is also provided.
Abstract: Provided herein are antigenic combinations and related compositions, methods and systems for immunizing a host from an infection caused by Francisella bacterium. The antigenic combination comprises an antigenic polysaccharide component from a Francisella bacterium capable of triggering a humoral immune response in an individual, a protein antigen component from the Francisella bacterium capable of triggering a cellular immune response in the individual, and an adjuvant, the antigenic Francisella polysaccharide component, the Francisella protein antigen component and the adjuvant are in a suitable amount to immunize an individual against the Francisella bacterium.
Type:
Grant
Filed:
August 16, 2019
Date of Patent:
November 8, 2022
Assignees:
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, REGENTS OF THE UNIVERSITY OF NEW MEXICO
Inventors:
Nicholas Fischer, Amy Rasley, Terry Wu, Julie Lovchik
Abstract: This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.
Type:
Grant
Filed:
October 4, 2017
Date of Patent:
November 1, 2022
Assignee:
ENGENEIC MOLECULAR DELIVERY PTY LTD
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A nutrient-germinant composition to aid in spore germination and a method for increased spore germination efficiency. The composition comprises L-amino acids, D-glucose and/or D-fructose, a phosphate buffer, an industrial preservative, and may include bacteria spores or they may be separately combined for germination. The method comprises providing a nutrient-germinant composition and bacteria spores, preferably of one or more Bacillus species, and heating to a preferred elevated temperature range of 41° C. to 44° C. for an incubation period of around 2 to 60 minutes. The nutrient-germinant composition is preferably in a concentrated liquid form that is diluted just prior to initiating the germination/incubation method at the point of use. The method may also include dispensing a germinated spore solution to a point-of-use/consumption, such as animal feed, water, or bedding, or a wastewater system or drain.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
November 1, 2022
Assignee:
NCH Corporation
Inventors:
Gabriel F. K. Everett, Charles Greenwald, Judy Pruitt, Amanda Rosmarin, Jordan Church, Daniel Aberle, George Aboagye
Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
Type:
Grant
Filed:
February 4, 2020
Date of Patent:
November 1, 2022
Assignees:
Janssen Pharmaceuticals, Inc.
Inventors:
Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
Abstract: The present invention relates to a novel use of a bacterial secretome in the field of the treatment of skin lesions and more particularly of wound healing. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial secretome as active agent.
Type:
Grant
Filed:
April 6, 2018
Date of Patent:
November 1, 2022
Assignee:
PIERRE FABRE DERMO-COSMETIQUE
Inventors:
Nathalie Castex-Rizzi, Marie Florence Galliano, Hélène Hernandez-Pigeon
Abstract: The present invention provides compositions and methods for treating, ameliorating, and/or preventing cocaine addiction in a subject. Immunization by M. vaccae alters serotonin signaling in the brain, reducing stress- and anxiety-like responding in animal models of post-traumatic stress disorder and other anxiety disorders. In certain embodiments, the immunoregulatory, anti-stress, and anxiolytic effects of M. vaccae immunization reduces addiction- and relapse-like responding in models of cocaine addiction and alter the development of cocaine-induced neuroinflammation.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
October 18, 2022
Assignees:
Rowan University, The Regents of the University of Colorado
Abstract: The invention relates to plasmids capable of expressing a protein targeting immune cells when transformed into a lactic acid bacterial cell, wherein the protein is chosen from the group consisting of murine and human CXCL12 1?; CXCL17 and Ym1. The invention further relates to lactic acid bacteria transformed with a said plasmid, as well as the use of said lactic acid bacteria for wound healing in humans and animals.
Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
Type:
Grant
Filed:
July 26, 2019
Date of Patent:
October 18, 2022
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventors:
Eric Pamer, Charlie Buffie, Peter McKenney
Abstract: Cold spot genes of S. pneumoniae are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the S. pneumoniae cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of S. pneumoniae, thus providing an improvement over currently available S. pneumoniae vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of S. pneumonia.
Abstract: The present invention concerns gp36 immunoreactive compositions for E. canis and gp 47 immunoreactive compositions for E. chaffeensis. In particular, epitopes for E. canis gp36 and E. chaffeensis gp 47 are disclosed. In certain embodiments, the immunoreactive compositions comprise tandem repeats having carbohydrate moieties.
Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
September 27, 2022
Assignee:
NEW YORK UNIVERSITY
Inventors:
Victor J. Torres, Tamara Reyes-Robles, Francis Alonzo, III